OrthoPediatrics (NASDAQ:KIDS) Posts Quarterly Earnings Results, Misses Expectations By $0.02 EPS

OrthoPediatrics (NASDAQ:KIDS) announced its quarterly earnings data on Tuesday. The company reported ($0.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.02), FiscalAI reports. The firm had revenue of $72.66 million for the quarter, compared to the consensus estimate of $68.50 million. OrthoPediatrics had a negative return on equity of 8.10% and a negative net margin of 15.72%.

OrthoPediatrics Price Performance

Shares of NASDAQ:KIDS traded down $0.20 during trading on Tuesday, reaching $23.82. The company had a trading volume of 372,691 shares, compared to its average volume of 180,975. The firm’s fifty day moving average is $23.04 and its 200 day moving average is $19.38. The firm has a market capitalization of $621.94 million, a PE ratio of -14.18 and a beta of 0.99. OrthoPediatrics has a twelve month low of $14.42 and a twelve month high of $26.74. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.17 and a current ratio of 4.78.

Insider Activity

In related news, major shareholder Squadron Capital Llc sold 326,700 shares of the business’s stock in a transaction that occurred on Friday, August 28th. The stock was sold at an average price of $23.04, for a total transaction of $7,527,168.00. Following the sale, the insider owned 6,536,764 shares of the company’s stock, valued at $150,607,042.56. The trade was a 4.76% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director David Pelizzon sold 326,700 shares of the business’s stock in a transaction that occurred on Friday, August 28th. The stock was sold at an average price of $23.04, for a total value of $7,527,168.00. Following the sale, the director directly owned 6,536,764 shares in the company, valued at approximately $150,607,042.56. The trade was a 4.76% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 2,100,000 shares of company stock worth $46,747,931 over the last three months. Corporate insiders own 32.50% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently commented on KIDS shares. Piper Sandler reaffirmed an “overweight” rating and issued a $25.00 price target (up from $22.00) on shares of OrthoPediatrics in a report on Wednesday, August 5th. BTIG Research reissued a “buy” rating and issued a $29.00 target price on shares of OrthoPediatrics in a report on Monday, September 14th. Truist Financial upgraded OrthoPediatrics to a “hold” rating in a research note on Thursday, October 1st. Weiss Ratings raised OrthoPediatrics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, August 5th. Finally, Needham & Company LLC upped their price target on shares of OrthoPediatrics from $30.00 to $35.00 and gave the stock a “buy” rating in a research report on Wednesday, August 5th. Five equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, OrthoPediatrics currently has a consensus rating of “Moderate Buy” and an average price target of $26.50.

OrthoPediatrics Company Profile

OrthoPediatrics Corp. is a medical device company focused exclusively on developing and commercializing orthopedic products for children. The company designs implants, instruments and related technologies intended to address the distinct anatomical and clinical needs of pediatric patients, including those with congenital conditions, traumatic injuries and musculoskeletal disorders.

Its product portfolio covers pediatric trauma and deformity correction, scoliosis, limb reconstruction, sports medicine and other specialized orthopedic procedures.